Unknown

Dataset Information

0

Identification of pathway-selective estrogen receptor ligands that inhibit NF-kappaB transcriptional activity.


ABSTRACT: Inflammation is now recognized as a key component in a number of diseases such as atherosclerosis, rheumatoid arthritis, and inflammatory bowel disease. The transcription factor NF-kappaB has been shown to be involved in both the early and late stages of the inflammatory-proliferative process. In this report, we describe the identification of the pathway-selective estrogen receptor (ER) ligand, WAY-169916, that inhibits NF-kappaB transcriptional activity but is devoid of conventional estrogenic activity. This pathway-selective ligand does not promote the classic actions of estrogens such as stimulation of uterine proliferation or ER-mediated gene expression, but is a potent antiinflammatory agent, as demonstrated in the HLA-B27 transgenic rat model of inflammatory bowel disease. Our results indicate the potential utility of pathway-selective ER ligands such as WAY-169916 in the treatment of chronic inflammatory diseases.

SUBMITTER: Chadwick CC 

PROVIDER: S-EPMC548967 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC2996265 | biostudies-literature
| S-EPMC2836031 | biostudies-literature
| S-EPMC2648135 | biostudies-literature
| S-EPMC3955358 | biostudies-literature
| S-EPMC3381613 | biostudies-literature
| S-EPMC2781422 | biostudies-literature
| S-EPMC2704748 | biostudies-literature
| S-EPMC2873845 | biostudies-literature
| S-EPMC2842467 | biostudies-literature
| S-EPMC3274540 | biostudies-other